| Peer-Reviewed

Single-pathogen and Mixed Vulvovaginal Infections Among Women of Reproductive Age Consulting Gynecologists: A Cross-Sectional Study

Received: 7 September 2021    Accepted: 23 September 2021    Published: 12 October 2021
Views:       Downloads:
Abstract

Vulvovaginal infections are a public health problem that accounts for 20% of gynecological consultations. However, there are no clear data on the prevalence of the different types of vulvovaginal infections, including vaginal mixed infections, that make women seek care from gynecologists. We aimed to determine the prevalence of vulvovaginal infections and to evaluate the therapeutic approach of symptomatic women of reproductive age consulting gynecologists. A cross-sectional study was conducted among 103 women with vulvovaginitis of probable infectious etiology at 25 gynecology outpatient clinics. Women underwent clinical diagnosis following standard clinical practice. Signs and symptoms were registered as well as the therapeutic strategy prescribed by the gynecologists and self-treatment habits of the women before consultation. A microbiological culture of the vaginal discharge was performed in all women to confirm the diagnosis. According to the microbiological studies, 68% of women had an infection, being candidiasis the most prevalent (54.3%), followed by bacterial vaginosis (25.7%), mixed infection (14.3%), and nonspecific vulvovaginitis (5.7%). Most of the candidiasis involved a single pathogen, however 19.4% were mixed infections also involving other pathogens. Leukorrhea and pruritus were the most prevalent symptoms (82.5% and 81.6% respectively). Mixed infections produced vaginal odor changes more often than single candidiasis (40% vs. 24%). Among the 103 women, 71.8% received pharmacological treatments, mostly antifungals, being fenticonazole the most frequently prescribed; 48.5% received nonpharmacological treatments, either alone or as adjuvant therapy. Candidiasis is the most prevalent vulvovaginal infection in symptomatic women of reproductive age consulting gynecologists. Candidiasis usually presents as a single-pathogen infection, but additional pathogens may coexist in many women. Clinical diagnosis of mixed infections is challenging because the most prevalent symptoms are the same as for candidiasis, so prescription of antifungals with a broad spectrum of antimycotic and antimicrobial activity is an adequate alternative for women.

Published in International Journal of Microbiology and Biotechnology (Volume 6, Issue 4)
DOI 10.11648/j.ijmb.20210604.11
Page(s) 95-103
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Antifungals, Bacterial Vaginosis, Gynecology, Mixed Infection, Pruritus, Vulvovaginal Candidiasis, Vulvovaginitis

References
[1] SEGO: Sociedad Española de Ginecología y Obstetricia. Diagnóstico y tratamiento de las infecciones vulvovaginales [Diagnosis and treatment of vulvovaginal infections] [Internet]. Madrid: SEGO. Spanish. 2018 Jan [cited 2021 Jun 3]. 24 p. Available from: www.sego.es.
[2] Mahur J, Humera A. A clinicoetiological study of vulvovaginitis in a tertiary care hospital. Int J Reprod Contracept Obstet Gynecol. 2019 Apr; 8 (5): 1999-2002.
[3] Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol Antimicrob [Internet]. 2020 Jan [cited 2021 Jun 3]; 19: 5. Available from: https://doi.org/10.1186/s12941-020-0347-4.
[4] Troyano-Luque JM. [Notes and reflections on local therapy for vulvovaginitis]. Prog Obstet Ginecol. 2019; 62 (3): 205-215. Spanish.
[5] Coudray MS, Madhivanan P. Bacterial vaginosis—A brief synopsis of the literature. Eur J Obstet Gynecol Reprod Biol. 2020 Feb; 245: 143-8.
[6] Sheppard C. Treatment of vulvovaginitis. Aust Prescr. 2020 Dec; 43 (6): 195-7.
[7] Felix TC, Araújo LB, Röder DVDB, Pedroso RS. Evaluation of Vulvovaginitis and Hygiene Habits of Women Attended in Primary Health Care Units of the Family. IJWH. 2020 Jan; 12: 49-57.
[8] Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018 Nov; 18 (11): 339-47.
[9] Landlinger C, Tisakova L, Oberbauer V, Schwebs T, Muhammad A, Latka A, et al. Engineered Phage Endolysin Eliminates Gardnerella Biofilm without Damaging Beneficial Bacteria in Bacterial Vaginosis Ex Vivo. Pathogens [Internet]. 2021 Jan [cited 2021 Jun 3]; 10 (1): 54. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830407/pdf/pathogens-10-00054.pdf.
[10] Tomás M, Palmeira-de-Oliveira A, Simões S, Martinez-de-Oliveira J, Palmeira-de-Oliveira R. Bacterial vaginosis: Standard treatments and alternative strategies. Int J Pharm [Internet]. 2020 Sep [cited 2021 Jun 3]; 587: 119659. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0378517320306438?via%3Dihub.
[11] Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sexual Trans Dis. 2019 May; 46 (5): 304-11.
[12] Neal CM, Kus LH, Eckert LO, Peipert JF. Noncandidal vaginitis: a comprehensive approach to diagnosis and management. Am J Obstet Gynecol. 2020 Feb; 222 (2): 114-22.
[13] Hillier SL, Austin M, Macio I, Meyn LA, Badway D, Beigi R. Diagnosis and Treatment of Vaginal Discharge Syndromes in Community Practice Settings. Clin Infect Dis. 2021 May; 72 (9): 1538-43.
[14] Peñas-Espinar C, Navarro-Sánchez-Ortiz MD, Olmo-Montes J, Muniáin-Ezcurra MA, Suárez-Barrenechea AI. [Diagnostic and therapeutic protocol for infectious vaginitis: candidal vulvovaginitis, trichomoniasis, and bacterial vaginosis]. Medicine. 2014; 11 (51): 3029-32. Spanish.
[15] Powell AM, Nyirjesy P. Recurrent vulvovaginitis. Best Pract Res Clin Obstet Gynaecol. 2014 Oct; 28 (7): 967-76.
[16] Lírio J, Giraldo PC, Amaral RL, Sarmento ACA, Costa APF, Gonçalves AK. Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol. BMJ Open [Internet]. 2019 May [cited 3 jun de 2021]; 9 (5): e027489.
[17] Sobel JD, Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin Pharmacother. 2018 Jun; 19 (9): 971-7.
[18] Tumietto F, Posteraro B, Sanguinetti M. Looking for appropriateness in the cure of mixed vaginitis: the role of fenticonazole as an empiric treatment. Future Microbiol. 2019 Nov; 14 (16): 1349-55.
[19] Obiero J, Rulisa S, Ogongo P, Wiysonge CS. Nifuratel-Nystatin combination for the treatment of mixed infections of bacterial vaginosis, vulvovaginal candidiasis, and trichomonal vaginitis. Cochrane Database of Systematic Reviews [Internet]. 2018 Apr [cited 3 junde 2021]; 4: CD013012. Available from: http://doi.wiley.com/10.1002/14651858.CD013012.
[20] Brown H, Drexler M. Improving the Diagnosis of Vulvovaginitis: Perspectives to Align Practice, Guidelines, and Awareness. Popul Health Manag. 2020 Oct; 23 (1): 3-12.
[21] Jaqueti-Aroca J, Ramiro-Martínez P, Molina-Esteban LM, Fernández-González AM, García-Arata I, Prieto-Menchero S, et al. Epidemiology and etiology of vulvovaginal candidiasis in Spanish and immigrants’ women in Fuenlabrada (Madrid). Rev Esp Quimioter. 2020 May; 33 (3): 187-92.
[22] Bolumburu C, Zamora V, Muñoz-Algarra M, Portero-Azorín F, Escario JA, Ibáñez-Escribano A. Trichomoniasis in a tertiary hospital of Madrid, Spain (2013–2017): prevalence and pregnancy rate, coinfections, metronidazole resistance, and endosymbiosis. Parasitol Res. 2020 Jun; 119 (6): 1915-23.
[23] Amores-Antequera C, Almazán-Alonso C, Cantudo-Muñoz P, Gómez-Fernández L. [Microbiological study of vulvovaginitis in prepuberal girls]. Rev Esp Quimioter. 2014; 27 (4): 271-2. Spanish.
[24] Nyirjesy P. Vulvovaginal Candidiasis and Bacterial Vaginosis. Infect Dis Clin North Am. 2008 Dec; 22 (4): 637-52.
[25] Farr A, Effendy I, Frey Tirri B, Hof H, Mayser P, Petricevic L, et al. Guideline: Vulvovaginal candidiasis (AWMF 015/072, level S2k). Mycoses. 2021 Feb; 64 (6): 583-602.
[26] Arellano-Moya DA. [Treatment of symptomatic vaginal discharge from mixed infections: Pharmacological options available in Costa Rica (Topic review)]. Acta Académica. 2017; 61: 139-54. Spanish.
[27] Felix TC, De Brito Röder DVD, Dos Santos Pedroso R. Alternative and complementary therapies for vulvovaginal candidiasis. Folia Microbiol. 2019 Mar; 64 (2): 133-41.
[28] Hanson L, Vande-Vusse L, Jermé M, Abad CL, Safdar N. Probiotics for Treatment and Prevention of Urogenital Infections in Women: A Systematic Review. J Midwifery Womens Health. 2016 May; 61 (3): 339-55.
[29] Jeng H, Yan T, Chen J. Treating vaginitis with probiotics in non-pregnant females: A systematic review and meta-analysis. Exp Ther Med. 2020 Aug; 20 (4): 3749-65.
[30] Tidbury FD, Langhart A, Weidlinger S, Stute P. Non-antibiotic treatment of bacterial vaginosis—a systematic review. Arch Gynecol Obstet. 2021 Jan; 303 (1): 37-45.
[31] Li C, Wang T, Li Y, Zhang T, Wang Q, He J, et al. Probiotics for the treatment of women with bacterial vaginosis: A systematic review and meta-analysis of randomized clinical trials. Eur J Pharmacol [Internet]. 2019 Dec [cited 2021 Jun 3]; 864: 172660. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0014299919306120?via%3Dihub.
[32] Xie HY, Feng D, Wei DM, Mei L, Chen H, Wang X, et al. Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database of Systematic Reviews [Internet]. 2017 Nov [cited 2021 jun 3]. Available from: http://doi.wiley.com/10.1002/14651858.CD010496.pub2.
[33] Cancelo-Hidalgo MJ, Neyro-Bilbao JL, Baquero-Úbeda JL. [Adjuvant treatment of vaginitis with probiotics. Degree of agreement based on the Delphi method]. Prog Obstet Ginecol. 2014 Jan; 57 (1): 4-13.
[34] Guinot M, Blanco JE, Delgado JL, Oliva R, Frutos LMS, Huerta I, et al. Acceptability, tolerability, and effects on symptoms and signs of vulvovaginitis of a non-soap, herbal-based intimate hygiene solution (Zelesse®). J Int Med Res. 2019 Jun; 47 (6): 2626-36.
[35] Yano J, Sobel JD, Nyirjesy P, Sobel R, Williams VL, Yu Q, et al. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Womens Health [Internet]. 2019 Dec [cited 2021 jun 3]; 19 (1): 48. Available form: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441174/.
[36] Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016 Jan; 214 (1): 15-21.
Cite This Article
  • APA Style

    Javier García Pérez-Llantada, Ana Rosa Masero, Jesús Lázaro-Carrasco, María José Carballo, Francisca Ridocci, et al. (2021). Single-pathogen and Mixed Vulvovaginal Infections Among Women of Reproductive Age Consulting Gynecologists: A Cross-Sectional Study. International Journal of Microbiology and Biotechnology, 6(4), 95-103. https://doi.org/10.11648/j.ijmb.20210604.11

    Copy | Download

    ACS Style

    Javier García Pérez-Llantada; Ana Rosa Masero; Jesús Lázaro-Carrasco; María José Carballo; Francisca Ridocci, et al. Single-pathogen and Mixed Vulvovaginal Infections Among Women of Reproductive Age Consulting Gynecologists: A Cross-Sectional Study. Int. J. Microbiol. Biotechnol. 2021, 6(4), 95-103. doi: 10.11648/j.ijmb.20210604.11

    Copy | Download

    AMA Style

    Javier García Pérez-Llantada, Ana Rosa Masero, Jesús Lázaro-Carrasco, María José Carballo, Francisca Ridocci, et al. Single-pathogen and Mixed Vulvovaginal Infections Among Women of Reproductive Age Consulting Gynecologists: A Cross-Sectional Study. Int J Microbiol Biotechnol. 2021;6(4):95-103. doi: 10.11648/j.ijmb.20210604.11

    Copy | Download

  • @article{10.11648/j.ijmb.20210604.11,
      author = {Javier García Pérez-Llantada and Ana Rosa Masero and Jesús Lázaro-Carrasco and María José Carballo and Francisca Ridocci and Manuel Sosa and Miguel González and Pedro Azumendi and María Palma and Concepción Nieto},
      title = {Single-pathogen and Mixed Vulvovaginal Infections Among Women of Reproductive Age Consulting Gynecologists: A Cross-Sectional Study},
      journal = {International Journal of Microbiology and Biotechnology},
      volume = {6},
      number = {4},
      pages = {95-103},
      doi = {10.11648/j.ijmb.20210604.11},
      url = {https://doi.org/10.11648/j.ijmb.20210604.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijmb.20210604.11},
      abstract = {Vulvovaginal infections are a public health problem that accounts for 20% of gynecological consultations. However, there are no clear data on the prevalence of the different types of vulvovaginal infections, including vaginal mixed infections, that make women seek care from gynecologists. We aimed to determine the prevalence of vulvovaginal infections and to evaluate the therapeutic approach of symptomatic women of reproductive age consulting gynecologists. A cross-sectional study was conducted among 103 women with vulvovaginitis of probable infectious etiology at 25 gynecology outpatient clinics. Women underwent clinical diagnosis following standard clinical practice. Signs and symptoms were registered as well as the therapeutic strategy prescribed by the gynecologists and self-treatment habits of the women before consultation. A microbiological culture of the vaginal discharge was performed in all women to confirm the diagnosis. According to the microbiological studies, 68% of women had an infection, being candidiasis the most prevalent (54.3%), followed by bacterial vaginosis (25.7%), mixed infection (14.3%), and nonspecific vulvovaginitis (5.7%). Most of the candidiasis involved a single pathogen, however 19.4% were mixed infections also involving other pathogens. Leukorrhea and pruritus were the most prevalent symptoms (82.5% and 81.6% respectively). Mixed infections produced vaginal odor changes more often than single candidiasis (40% vs. 24%). Among the 103 women, 71.8% received pharmacological treatments, mostly antifungals, being fenticonazole the most frequently prescribed; 48.5% received nonpharmacological treatments, either alone or as adjuvant therapy. Candidiasis is the most prevalent vulvovaginal infection in symptomatic women of reproductive age consulting gynecologists. Candidiasis usually presents as a single-pathogen infection, but additional pathogens may coexist in many women. Clinical diagnosis of mixed infections is challenging because the most prevalent symptoms are the same as for candidiasis, so prescription of antifungals with a broad spectrum of antimycotic and antimicrobial activity is an adequate alternative for women.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Single-pathogen and Mixed Vulvovaginal Infections Among Women of Reproductive Age Consulting Gynecologists: A Cross-Sectional Study
    AU  - Javier García Pérez-Llantada
    AU  - Ana Rosa Masero
    AU  - Jesús Lázaro-Carrasco
    AU  - María José Carballo
    AU  - Francisca Ridocci
    AU  - Manuel Sosa
    AU  - Miguel González
    AU  - Pedro Azumendi
    AU  - María Palma
    AU  - Concepción Nieto
    Y1  - 2021/10/12
    PY  - 2021
    N1  - https://doi.org/10.11648/j.ijmb.20210604.11
    DO  - 10.11648/j.ijmb.20210604.11
    T2  - International Journal of Microbiology and Biotechnology
    JF  - International Journal of Microbiology and Biotechnology
    JO  - International Journal of Microbiology and Biotechnology
    SP  - 95
    EP  - 103
    PB  - Science Publishing Group
    SN  - 2578-9686
    UR  - https://doi.org/10.11648/j.ijmb.20210604.11
    AB  - Vulvovaginal infections are a public health problem that accounts for 20% of gynecological consultations. However, there are no clear data on the prevalence of the different types of vulvovaginal infections, including vaginal mixed infections, that make women seek care from gynecologists. We aimed to determine the prevalence of vulvovaginal infections and to evaluate the therapeutic approach of symptomatic women of reproductive age consulting gynecologists. A cross-sectional study was conducted among 103 women with vulvovaginitis of probable infectious etiology at 25 gynecology outpatient clinics. Women underwent clinical diagnosis following standard clinical practice. Signs and symptoms were registered as well as the therapeutic strategy prescribed by the gynecologists and self-treatment habits of the women before consultation. A microbiological culture of the vaginal discharge was performed in all women to confirm the diagnosis. According to the microbiological studies, 68% of women had an infection, being candidiasis the most prevalent (54.3%), followed by bacterial vaginosis (25.7%), mixed infection (14.3%), and nonspecific vulvovaginitis (5.7%). Most of the candidiasis involved a single pathogen, however 19.4% were mixed infections also involving other pathogens. Leukorrhea and pruritus were the most prevalent symptoms (82.5% and 81.6% respectively). Mixed infections produced vaginal odor changes more often than single candidiasis (40% vs. 24%). Among the 103 women, 71.8% received pharmacological treatments, mostly antifungals, being fenticonazole the most frequently prescribed; 48.5% received nonpharmacological treatments, either alone or as adjuvant therapy. Candidiasis is the most prevalent vulvovaginal infection in symptomatic women of reproductive age consulting gynecologists. Candidiasis usually presents as a single-pathogen infection, but additional pathogens may coexist in many women. Clinical diagnosis of mixed infections is challenging because the most prevalent symptoms are the same as for candidiasis, so prescription of antifungals with a broad spectrum of antimycotic and antimicrobial activity is an adequate alternative for women.
    VL  - 6
    IS  - 4
    ER  - 

    Copy | Download

Author Information
  • Gynecological Center Doctor García Pérez-LLantada SL, Zaragoza, Spain

  • Centro Sur Clinic, Madrid, Spain

  • Arpa Médica Darro, Madrid, Spain

  • HM Belén Maternity, A Coru?a, Spain

  • RYD Maternity Clinic, Valencia, Spain

  • Department of Gynecology & Obstetrics, Perpetuo Socorro Hospital, Las Palmas de Gran Canaria, Spain

  • Miguel González SLP Clinic, Valencia, Spain

  • Gutenberg Gynecological Center, Málaga, Spain

  • ITF Research Pharma SLU, Madrid, Spain

  • ITF Research Pharma SLU, Madrid, Spain

  • Sections